Long lasting synthetic glucagon like peptide (GLP-1)
6 Assignments
0 Petitions
Accused Products
Abstract
Modified insulinotropic peptides are disclosed. The modified insulinotropic peptides are capable of forming a peptidase stabilized insulinotropic peptide. The modified insulinotropic peptides are capable of forming covalent bonds with one or more blood components to form a conjugate. The conjugates may be formed in vivo or ex vivo. The modified peptides are administered to treat humans with diabetes and other related diseases.
-
Citations
39 Claims
-
1-19. -19. (canceled)
-
20. A method for treating an insulinotropic peptide related disease in a patient, comprising administering to the patient an effective amount of a modified insulinotropic peptide comprising SEQ ID NO:
- 18 wherein said insulinotropic peptide related disease is obesity.
- View Dependent Claims (21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39)
Specification